Monday, April 27, 2015

In conversation with Dr. Shai Yarkoni

In conversation with Dr. Shai Yarkoni

April 21, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=VRkLBen0HaE’]

Tweet As a co-founder and CEO of Cellect Biotechnology (TASE:CLBD), Dr. Shai Yarkoni has more than 15 years of clinical and management experience in the biopharmaceutical industry. He is the founder of five start-ups in the life-sciences field, and serves on the board of noted institutes in Israel and the world. Prior to founding Cellect, […]

In conversation with Greg Trudel

In conversation with Greg Trudel

April 14, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=7TkiF1ODwWg’]

Tweet As president and CEO of Encision (OTCQB:ECIA), Greg Trudel, who moved into the executive suite in December 2013, has always had a strong interest in energy, dating back to various leadership posts with ConMed Electrosurgery, SilverGlide Surgical Technologies, and Stryker. Most recently, he was global director of marketing for a division within the Surgical Solutions […]

Relmada championing four pain drug candidates

Relmada championing four pain drug candidates

April 7, 2015 by · Leave a Comment 

Tweet Startup Relmada Therapeutics (OTCQB:RLMD) is in the enviable position of having multiple shots on goal in the world’s largest drug prescription market: the treatment of pain. “It is very unusual for a startup or even a mid-sized biotech company to have four different medications in clinical development for pain relief,” Dr. Eliseo Salinas, president […]

In conversation with Dr. Isaac Ciechanover

In conversation with Dr. Isaac Ciechanover

March 31, 2015 by · Leave a Comment 

Tweet As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He was a former partner in the life sciences practice at Kleiner Perkins Caufield & Byers and spent a decade as Celgene’s executive […]

Actinium gearing up for pivotal trial in second half

Actinium gearing up for pivotal trial in second half

March 24, 2015 by · Leave a Comment 

Tweet Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute myeloid leukemia (AML) prior to a bone marrow transplant (BMT). The company also has a second drug candidate, Actimab-A, now in a […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

CombiMatrix sets bold three-year vision

CombiMatrix sets bold three-year vision

March 10, 2015 by · Leave a Comment 

Tweet Mark McDonough, president and CEO of CombiMatrix (NASDAQ:CBMX), has set a bold three-year vision for the clinical diagnostic lab company, which specializes in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. “We’d like to grow the company to a market cap of at least $125-million, with revenue north of $40-million in […]

Synergy Disc Replacement sets global sales plan

Synergy Disc Replacement sets global sales plan

March 3, 2015 by · Leave a Comment 

Tweet After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution aggressively in Europe, Asia Pacific and other parts of the world. “We are also in the early stages of developing our U.S. regulatory strategy to gain […]

In conversation with Steve Damon

In conversation with Steve Damon

February 24, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=F4gEY5O0EcU’]

Tweet As president, CEO and a co-founder of closely-held 4P Therapeutics, a leading developer of transdermal patches, Steve Damon cut his teeth in the sector at Altea Therapeutics and Durect. He was responsible for executing several key partnerships with various pharmaceutical companies for Altea’s novel transdermal patch technology, bringing over $45-million of non-dilutive financing to Altea. Prior […]

Neovasc launching Reducer in Europe for RA

Neovasc launching Reducer in Europe for RA

February 17, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=LdK0CXdhgDo’]

Tweet Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. “Our aim is have distributors selling Reducer in Switzerland, Italy and the UK, while in Germany, we’ll use a combination of distributors and our own sales […]

Next Page »

Email Newsletters with Constant Contact
Google+